Math Biology has been officially selected to join the U.S. Market Gateway Accelerator for BioSciences and MedTech, a prestigious international program based in Philadelphia, aimed at supporting the global growth of innovative companies in the life sciences and medical technology sectors.

The program offers selected companies access to key resources in the U.S. healthcare ecosystem — from strategic mentorship and regulatory guidance, to investor relations and clinical validation. For Math Biology, this represents a strategic milestone in its international journey, unlocking the U.S. market with structured support and unparalleled networking opportunities.

The accelerator is supported by the University City Science Center, a hub of innovation in Philadelphia, and is recognized for catalyzing the growth of high-potential startups entering the North American market.

By participating, Math Biology strengthens its mission to redefine early diagnostics and personalized medicine through its proprietary DMA® technology, an AI-powered, non-invasive tool capable of identifying early metabolic imbalances with precision and scalability.

This achievement not only validates Math Biology’s clinical and technological approach but also positions the company at the forefront of next-generation health innovation on a global scale.